EA201992059A1 - PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL - Google Patents

PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL

Info

Publication number
EA201992059A1
EA201992059A1 EA201992059A EA201992059A EA201992059A1 EA 201992059 A1 EA201992059 A1 EA 201992059A1 EA 201992059 A EA201992059 A EA 201992059A EA 201992059 A EA201992059 A EA 201992059A EA 201992059 A1 EA201992059 A1 EA 201992059A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunogenous
peptides
platform
identification
methods
Prior art date
Application number
EA201992059A
Other languages
Russian (ru)
Inventor
Юлианна Лисиэиц
Левенте Мольнар
Эникё Р. Тёке
Йожеф ТОТ
Оршойа Лоринц
Жольт Чисовски
Эстер Шомодьи
Каталин Пантья
Моника Медьеши
Original Assignee
Треош Био Зрт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Треош Био Зрт filed Critical Треош Био Зрт
Priority claimed from PCT/EP2018/055232 external-priority patent/WO2018158457A1/en
Publication of EA201992059A1 publication Critical patent/EA201992059A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к способам идентификации фрагментов полипептида, которые являются иммуногенными для конкретного субъекта-человека, способам получения фармацевтических композиций, содержащих такие полипептидные фрагменты, фармацевтическим композициям, содержащим такие полипептидные фрагменты, и способам лечения с использованием таких композиций. Способы включают идентификацию фрагмента полипептида, который связывается с множеством HLA отдельных субъектов.The present invention relates to methods for identifying fragments of a polypeptide that are immunogenic for a particular human subject, methods for producing pharmaceutical compositions containing such polypeptide fragments, pharmaceutical compositions containing such polypeptide fragments, and methods of treatment using such compositions. The methods include identifying a fragment of a polypeptide that binds to multiple HLAs of individual subjects.

EA201992059A 2017-03-09 2018-03-02 PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL EA201992059A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703809.2A GB201703809D0 (en) 2017-03-09 2017-03-09 Vaccine
PCT/EP2018/055232 WO2018158457A1 (en) 2017-03-03 2018-03-02 Population-based immunogenic peptide identification platform

Publications (1)

Publication Number Publication Date
EA201992059A1 true EA201992059A1 (en) 2020-03-31

Family

ID=58605461

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201992058A EA201992058A1 (en) 2017-03-09 2018-03-02 VACCINE
EA201992057A EA201992057A1 (en) 2017-03-09 2018-03-02 PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE
EA201992059A EA201992059A1 (en) 2017-03-09 2018-03-02 PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201992058A EA201992058A1 (en) 2017-03-09 2018-03-02 VACCINE
EA201992057A EA201992057A1 (en) 2017-03-09 2018-03-02 PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE

Country Status (2)

Country Link
EA (3) EA201992058A1 (en)
GB (1) GB201703809D0 (en)

Also Published As

Publication number Publication date
EA201992057A1 (en) 2020-03-06
GB201703809D0 (en) 2017-04-26
EA201992058A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
CO2019010524A2 (en) Population-based immunogenic peptide identification platform
CY1124867T1 (en) SINGLE REGION ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS
EA201992063A1 (en) BINDING ErbB-2 AND ErbB-3 SPECIFIC ANTIBODIES FOR USE FOR TREATMENT OF CELLS THAT CONTAIN THE NRG-1 FUSED GENE
EA201892548A1 (en) ANTIBODIES TO ALPHA-SINUCULINE AND THEIR APPLICATION
EA201792573A1 (en) TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION
EA201890640A1 (en) RECOMBINANT VECTORS CONTAINING PEPTIDE 2A
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
CY1124143T1 (en) BONE MORPHOGENETIC PROTEINS
CY1125150T1 (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
AR110114A1 (en) ANTIBODIES AGAINST b-AMYLOID PIROGLUTAMATO AND ITS USES
EA201792561A1 (en) ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
CY1121734T1 (en) MUTANT OspA FRAGMENTS AND METHODS AND USES THEREOF
MX2019003970A (en) Immunogenic arginase peptides.
EA202091095A1 (en) ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGUES
CY1126031T1 (en) COMPOSITIONS FOR CLEANSING THE COLON AND TREATMENT OF GASTROINTESTINAL DISORDERS
MX2021007589A (en) Anti-il-36 antibodies and methods of use thereof.
EA202190647A1 (en) ANTIBODIES TO KLRG1
EA202192488A1 (en) ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
EA202092281A1 (en) ANTI-PfRH5 ANTIBODIES AND THEIR ANTIGEN-BINDING FRAGMENTS
EA202191758A1 (en) PEPTIDES FOR THE TREATMENT AND PREVENTION OF DIABETES AND RELATED DISEASES
EA201992059A1 (en) PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL
CY1122445T1 (en) POTASSIUM CHANNEL COMPETITORS KV1.3
EA202190045A1 (en) COMPOSITIONS / COMPOSITIONS CONTAINING IBRUTINIB